AOD 9604 side effects
AOD 9604 was deliberately engineered to avoid the side effects of full-length growth hormone. Here's what the clinical trial data actually reported, what injection-site and oral-formulation reactions look like, and the safety questions that remain open.
- In Metabolic Pharmaceuticals' Phase II trials, AOD 9604 was generally well tolerated with no statistically significant difference in serious adverse events versus placebo.
- Unlike full-length hGH, AOD 9604 does not cause fluid retention, carpal tunnel syndrome, or insulin resistance at studied doses.
- The most commonly reported injection site reactions include mild redness, itching, and transient bruising.
- Troche and lozenge formulations may cause oral irritation and altered taste rather than systemic effects.
- Long-term safety data beyond 12 weeks does not exist — nearly all published trials ran 12 weeks or less.
What the clinical trial data showed
AOD 9604's safety profile is one of the most reassuring parts of its clinical development record — and also one of the reasons it circulated in peptide communities long after Metabolic Pharmaceuticals ended the obesity program. In the Phase IIa and IIb trials, which together dosed several hundred overweight and obese adults for up to 12 weeks, AOD 9604 produced no statistically significant increase in serious adverse events compared with placebo.
That is unusual. Most investigational weight-loss drugs run into dose-limiting toxicity, cardiovascular signals, or GI intolerance. AOD 9604 did not. The reason is structural: the molecule was engineered specifically to isolate the lipolytic activity of hGH from the side effects that make full-length hGH unsuitable as a chronic obesity therapy.
AOD 9604 side effects: what was reported
The published AOD 9604 side effect profile, drawn from the Phase IIa and IIb obesity trials, can be summarized as follows:
| Side effect | Frequency vs. placebo | Notes |
|---|---|---|
| Headache | Mildly elevated | Generally transient, first 1–2 weeks of dosing |
| Nausea | Similar to placebo | Notably lower than GLP-1 agonists |
| Injection site redness | Common in subcutaneous protocols | Usually self-limited; rotate sites |
| Injection site itching | Common | Mild; resolves within hours |
| Fatigue | Minimal signal | Not dose-related in reported data |
| Insulin resistance | None observed | Key differentiator from hGH |
| Fluid retention / edema | None observed | Key differentiator from hGH |
| IGF-1 elevation | None observed | Confirmed in PK studies |
| Carpal tunnel | None reported | Classic hGH side effect; absent here |
Why AOD 9604 side effects are different from hGH
Full-length human growth hormone, used at pharmacologic doses, produces a well-characterized set of side effects: fluid retention, joint pain, carpal tunnel syndrome, gynecomastia, insulin resistance, and — with prolonged use — an increased risk of type 2 diabetes. These effects are driven largely by hGH's binding to its receptor in liver, muscle, and other tissues and its downstream stimulation of IGF-1 production.
AOD 9604 was deliberately designed to avoid this. By keeping only the C-terminal lipolytic fragment of hGH and discarding the receptor-binding regions, the molecule loses nearly all of the classic growth-hormone side effects. Human PK studies have confirmed that AOD 9604 administration does not raise IGF-1 levels, which is the most important mechanistic distinction.
Injection site reactions
Subcutaneous peptide injections, including AOD 9604, commonly cause mild local reactions. These include redness, a small raised bump at the injection site, brief itching, and occasional bruising. These reactions are almost always self-limited and resolve within hours. Strategies that reduce them include:
- Rotating injection sites (abdomen, thigh, upper arm) to avoid irritating the same spot repeatedly
- Using a fresh 29- or 31-gauge insulin syringe per injection
- Warming the reconstituted peptide to room temperature before injecting
- Injecting slowly to minimize local pressure
AOD 9604 troche and oral side effects
AOD 9604 has been compounded in oral forms including troches (lozenges), capsules, tablets, and nasal sprays. These formulations have a different side effect pattern because very little peptide reaches systemic circulation. AOD 9604 troche side effects reported anecdotally are limited to mild oral irritation, altered taste, and occasional dry mouth. Systemic side effects from oral formulations are rare — a consequence of the poor oral bioavailability that ultimately limited the drug's clinical development.
What we don't know
The most important limitation in AOD 9604's safety record is duration. Almost every published trial ran for 12 weeks or less. There is no long-term safety data — nothing beyond 3 months of continuous dosing, and no data at all in children, pregnant women, or patients with hepatic or renal impairment. The molecule's safety at higher chronic subcutaneous doses (in the 500 mcg/day range commonly used outside clinical settings) has not been formally evaluated.
Safety note
The favorable AOD 9604 side effect profile in clinical trials does not make the compound safe for unsupervised use. Peptides sold through gray-market research chemical suppliers are not tested for purity, identity, endotoxin contamination, or sterility. The bulk of the safety record above applies to pharmaceutical-grade material administered in a controlled clinical setting — not to arbitrary vials purchased online.
Frequently asked questions
What are the most common AOD 9604 side effects?
In clinical trials the most common reported effects were mild headache (in the first 1–2 weeks), transient injection site redness and itching, and occasional fatigue. Serious adverse events were not significantly different from placebo.
Does AOD 9604 cause insulin resistance?
No. Unlike full-length growth hormone, AOD 9604 does not raise IGF-1 and does not cause insulin resistance at studied doses. This was one of the primary design goals of the molecule.
Are there long-term AOD 9604 side effects?
There is no published long-term human safety data. Clinical trials ran for 12 weeks or less. Anything beyond that duration is unstudied territory.
Do AOD 9604 troches have the same side effects as injections?
No. Because oral bioavailability is very low, troche and lozenge formulations tend to produce only local oral effects (mild irritation, taste changes) rather than systemic side effects.
Is AOD 9604 safer than semaglutide?
In terms of the GI side effects that dominate the semaglutide tolerability profile — nausea, vomiting, constipation — AOD 9604 is significantly better tolerated. It does not act on GLP-1 receptors and does not affect gut motility. However, AOD 9604 is also far less effective for weight loss, so the risk-benefit comparison is not direct.